Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zorecimeran - CureVac

Next Previous
Drug Profile

Zorecimeran - CureVac

Alternative Names: Coronavirus vaccine - CureVac; CV07050101; CVnCoV vaccine - CureVac; nCoV-2019 vaccine - CureVac

Latest Information Update: 04 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CureVac
  • Class COVID-19 vaccines; RNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration COVID 2019 infections

Most Recent Events

  • 08 Jun 2022 CureVac completes a phase III trial in COVID-2019 infections (Prevention, In adults, In elderly) in Germany (Intramuscular, Injection) (NCT04674189)
  • 03 Jun 2022 CureVac AG completes a phase-II/III trial in COVID-2019 infections (Prevention) in Belgium, Germany, Mexico, Netherlands, Peru, Argentina, Colombia, Dominican Republic, Panama and Spain (IM) (NCT04652102)(EudraCT 2020-003998-22)
  • 13 May 2022 CureVac terminates a phase III trial in COVID-2019 infections (Prevention) in Belgium (IM) (EudraCT2020-004070-22) (NCT04860258)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top